AELIS FARMA
A clinical stage biotech company opening a new frontier in pharmacology
33 employees · est. 2013 · France
Longboard Pharmaceuticals
We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.
81 employees · est. 2020 · La Jolla, United States
AELIS FARMA is the older company (2013 vs 2020); Longboard Pharmaceuticals is the larger of the two.
Side-by-Side Comparison
| Metric | AELIS FARMA | Longboard Pharmaceuticals |
|---|---|---|
| Founded | ||
| Founded | 2013 older | 2020 |
| Headquarters | ||
| Headquarters | France | La Jolla, United States |
| Employees | ||
| Employees | 33 | 81 larger |
| Industry | ||
| Industry | Not tracked yet | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | IPO | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $40.46M | $79.00M |
| Funding Rounds | ||
| Funding Rounds | 5 | 3 |
| Services | ||
| Services | Development of pharmacological inhibitors, Innovative drug formulation, Clinical trials for brain diseases | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with brain diseases, Individuals with cannabis related disorders, People experiencing cognitive deficits, Patients with Down syndrome | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Clinical Stage Biopharmaceuticals, Brain Diseases Treatment, Endocannabinoid System, CB1 Receptor, Signaling Specific Inhibitors, Cannabis Use Disorders, Cognitive Deficits, Down Syndrome, Pharmacology Innovation, GPCR Targeting, Allosteric Modulators, Central Nervous System, Therapeutic Drug Development, Neuropathology | Biopharmaceutical Company, Clinical-stage, Neurological Diseases, G Protein-coupled Receptors, Small Molecule Product Candidates, 5-hydroxytryptamine 2C (5-HT2C) Receptor, Epileptic Encephalopathies, Sphingosine-1-phosphate (S1P) Receptor, Multiple Neurological Diseases, Cannabinoid Type 2 Receptor (CB2), Central Nervous System (CNS), Drug Development, Clinical Trials, Neurological Research, Translational Medicine |
| Website | ||
| Website | aelisfarma.com | longboardpharma.com |
About AELIS FARMA
AELIS FARMA, founded in 2013, is a pioneering biopharmaceutical company based in France. The company is a frontrunner in developing treatments for brain diseases, focusing on a unique drug class known as Signaling Specific inhibitors of the CB1 receptor—a novel approach with transformative potential...
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a mission to revolutionize the lives of patients affected by neurological and rare diseases. The company is dedicated to developing groundbreaking medications for neurological conditions by focusing on a portfolio of...
We will tell you when either one moves
BounceWatch watches AELIS FARMA and Longboard Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at AELIS FARMA and Longboard Pharmaceutic... — by email.
Frequently Asked Questions
Compare AELIS FARMA with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at AELIS FARMA on 9 Apr 2026, and Longboard Pharmaceuticals on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
